Grace Hampson - OHE

Exploring the Financial Sustainability of Gene Therapies

News
October 2020

Opportunities to Increase Efficiency in Healthcare

Health Policy and Regulation

Opportunities to Increase Efficiency in Healthcare

HTA and Payment Mechanisms for New Drugs to Tackle AMR

Health Policy and Regulation

Public Health and Economic Implications of the United Kingdom Exiting the EU and the Single Market

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

$Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) report cover$

News & Insights

Latest Research & Publications

All Publications

We found for

Filter results by

Exploring the Financial Sustainability of Gene Therapies

Opportunities to Increase Efficiency in Healthcare

Opportunities to Increase Efficiency in Healthcare

HTA and Payment Mechanisms for New Drugs to Tackle AMR

Public Preferences for Health Gains and Cures: A Discrete Choice Experiment

Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions

Real World Evidence for Coverage Decisions: Opportunities and Challenges

Public Health and Economic Implications of the United Kingdom Exiting the EU and the Single Market

‘Macro’ Evaluation of the NIHR Oxford Biomedical Research Centre

Transferability of HTA

How can HTA meet the needs of health system and government decision makers?

Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement: Principles and Practice, with Special Reference to High Cost Technologies

Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value

Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

Four Case Studies to Explore the Added Value of Oxford AHSN

Share on Mastodon